Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Oral CEM-101 vs Levofloxacin in CABP
NCT01168713Phase 2Completed
- Sponsor
- Melinta Therapeutics
- Start
- Aug 2010
- Primary completion
- Jul 2011
- Modality
- RNA-Targeting Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of solithromycin in community-acquired bacterial pneumonia (CAP), sponsored by Melinta Therapeutics. Started Aug 2010; status: completed.
02
Drugs
solithromycin
03
Conditions
community-acquired bacterial pneumonia (CAP)
Beyond the preview
Go deeper on NCT01168713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01168713.